| |
| |
|
| Insider
Information: |
Alton Gregg H |
| Relationship: |
Director |
| City: |
Foster City |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
61,846 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,932,241 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
61,846 |
|
|
| Total
Value |
$3,932,241 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Gilead Sciences Inc |
GILD |
Chief Patient Officer |
2019-02-15 |
58,046 |
2018-02-20 |
0 |
Premium* |
|
|
Novavax Inc |
NVAX |
Director |
2023-06-10 |
3,800 |
2022-06-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
360 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 15
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GILD |
Gilead Sciences Inc |
Chief Patient Officer |
• • – |
2019-02-15 |
4 |
A |
$57.45 |
$18,959 |
D/D |
330 |
58,046 |
0 |
- |
|
| NVAX |
Novavax Inc |
Director |
– • – |
2022-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
700 |
700 |
0 |
- |
|
| NVAX |
Novavax Inc |
Director |
– • – |
2023-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,100 |
3,800 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2016-09-22 |
4 |
AS |
$81.84 |
$409,220 |
D/D |
(5,000) |
132,964 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2016-11-09 |
4 |
AS |
$79.00 |
$790,000 |
D/D |
(10,000) |
122,964 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-02-15 |
4 |
A |
$59.33 |
$18,689 |
D/D |
315 |
123,279 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,716 |
130,995 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-02-16 |
4 |
D |
$70.31 |
$462,429 |
D/D |
(6,577) |
124,418 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-02-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,430 |
122,988 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-03-30 |
4 |
S |
$67.48 |
$337,392 |
D/D |
(5,000) |
117,988 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-05-01 |
4 |
AS |
$68.31 |
$341,529 |
D/D |
(5,000) |
112,988 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-06-01 |
4 |
AS |
$65.02 |
$325,114 |
D/D |
(5,000) |
107,988 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-07-03 |
4 |
AS |
$71.06 |
$355,295 |
D/D |
(5,000) |
102,988 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-07-21 |
4 |
OE |
$26.99 |
$931,155 |
D/D |
34,500 |
137,488 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-07-21 |
4 |
AS |
$74.00 |
$2,960,000 |
D/D |
(40,000) |
97,488 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-08-01 |
4 |
OE |
$26.99 |
$232,789 |
D/D |
8,625 |
106,113 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-08-01 |
4 |
AS |
$75.88 |
$1,138,190 |
D/D |
(15,000) |
91,113 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-08-30 |
4 |
OE |
$24.91 |
$1,117,815 |
D/D |
43,125 |
134,238 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-08-30 |
4 |
AS |
$79.00 |
$3,950,000 |
D/D |
(50,000) |
84,238 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-09-01 |
4 |
AS |
$82.96 |
$2,076,188 |
D/D |
(25,000) |
76,488 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-09-01 |
4 |
OE |
$24.91 |
$429,611 |
D/D |
17,250 |
101,488 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-10-02 |
4 |
OE |
$24.91 |
$429,611 |
D/D |
17,250 |
93,738 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-10-02 |
4 |
AS |
$81.84 |
$2,066,307 |
D/D |
(25,000) |
68,738 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-11-01 |
4 |
OE |
$24.91 |
$214,806 |
D/D |
8,625 |
77,363 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-11-01 |
4 |
AS |
$74.74 |
$1,122,285 |
D/D |
(15,000) |
62,363 |
0 |
- |
|
360 Records found
|
|
Page 1 of 15 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
